• TRPV1 and TRPA1 in Nasal Epithelial TSLP

  2026-10-07

  The 2024 reference study links TRPV1 and TRPA1 activation in nasal epithelial cells to calcium-dependent NFAT signaling and increased TSLP production. Its main contribution is to connect epithelial TRP channel activity with inflammatory alarmin responses, while also showing that the evidence for TSLP is stronger than for related cytokines.

• gamma-Glu-Cys Product Overview

  2026-10-07

  Supplier-described gamma-Glu-Cys (γ-Glu-Cys; SKU B7887) is a research-use biochemical associated with glutathione biosynthesis and phytochelin formation. No matched paper evidence was available, so its performance and biological applicability cannot be independently assessed.

• Drug-Sensitized Yeast for mTOR Inhibitor Discovery

  2026-10-06

  A 2025 GeroScience study developed a genetically drug-sensitized Saccharomyces cerevisiae platform for detecting TOR/mTOR pathway inhibitors with substantially greater sensitivity than a wild-type yeast background. The system distinguished known inhibitors, identified aminophylline as a TOR1-dependent growth inhibitor, and found no evidence of TOR inhibition for several tested compounds, including nebivolol, within the assay model.

• CUDC-907 Product Overview

  2026-10-06

  CUDC-907 (SKU A4097) is an APExBIO research product described as a dual PI3K and HDAC inhibitor. The supplied materials establish its product identity and conceptual cancer-research scope, but no matched paper evidence is available to independently validate performance or applicability.

• Adefovir Dipivoxil in Chronic HBV: Evidence and Mechanism

  2026-10-05

  Hadziyannis and Papatheodoridis synthesized preclinical and clinical evidence positioning adefovir dipivoxil as an oral nucleotide analog antiviral for chronic hepatitis B, including HBeAg-positive, HBeAg-negative, and lamivudine-resistant disease. The review’s central contribution is its connection of selective HBV DNA polymerase inhibition with durable virologic activity, relatively low resistance, and the need to interpret long-term safety in relation to renal function.

• Canagliflozin and Mitochondrial Kidney Research

  2026-10-05

  A source-grounded overview of how canagliflozin was associated with proximal-tubule mitochondrial remodeling in hypertensive–diabetic mice, what the findings suggest about renal protection, and why the evidence remains preclinical and model-specific.

• ddhCTP and Viperin: From Mechanism to Translation

  2026-10-04

  A source-grounded analysis of ddhCTP, viperin biology, flaviviral RNA synthesis interruption, and the emerging evidence that viperin can also suppress coronavirus replication through nsp8-dependent disruption of replication-transcription complex assembly.

• Anagliptin: From DPP-4 to Vascular Tone

  2026-10-03

  Anagliptin and SK-0403 are best known for selective DPP-4 inhibition, but recent rabbit-aorta evidence points to a distinct vascular smooth-muscle phenotype. This article evaluates the Kv channel and SERCA findings, separates established results from interpretation, and defines the translational limits of the evidence.

• Cardamomin and Oxidative Stroke Injury

  2026-10-02

  The reference study shows that cardamomin from Amomum villosum stems and leaves protects against hydrogen peroxide-induced oxidative injury in BV-2 cells and reduces damage in a rat model of permanent cerebral ischemia. Its main innovation is a mechanistic framework connecting MEK/ERK-dependent NRF2 activation with suppression of oxeiptosis, parthanatos, DNA damage, and tissue injury.

• Go 6983 and the Logic of PKC-Centered Translation

  2026-10-01

  Translational research increasingly depends on connecting signaling perturbations with cell fate and metabolism rather than treating each phenotype as an isolated endpoint. This thought-leadership article examines how Go 6983, a pan-PKC inhibitor, can be used to interrogate PKC-dependent biology while placing recent WDR36–glycolysis findings in the proper evidentiary context.

• ML385 and NRF2: A Translational Research Playbook

  2026-10-01

  ML385 offers a practical way to interrogate NRF2-dependent stress adaptation, ferroptosis, and therapeutic resistance. This thought-leadership guide connects evidence from non-small cell lung cancer research with ferroptosis-focused liver studies and outlines a disciplined path from pathway inhibition to translational insight.

• InstaBlue Protein Stain Solution in Cell Assays

  2026-09-30

  This scenario-based guide explains how InstaBlue Protein Stain Solution, SKU B8226, can strengthen protein-level quality control alongside cell viability, proliferation, and cytotoxicity assays. It covers compatibility, rapid staining, interpretation limits, safety, and vendor-selection criteria using product specifications and relevant biomedical literature.

• 7ACC2 and the Metabolic Logic of Tumor Lactate

  2026-09-30

  7ACC2 is a potent monocarboxylate transporter 1 inhibitor that connects lactate flux, mitochondrial pyruvate handling, radiosensitization, and emerging tumor–immune metabolic biology. This thought-leadership perspective interprets its preclinical evidence, outlines validation strategies, and explains how researchers can position 7ACC2 within translational cancer metabolism research without overstating its clinical maturity.

• Intestinal Stretch, Weight Loss, and Satiety Recovery

  2026-09-29

  A 2025 Molecular Metabolism study shows that intestinal stretch suppresses feeding and improves oral glucose tolerance through mechanisms that are not dependent on GLP-1 signaling or classical intestinal nutrient sensing. Obesity weakened this response, whereas dietary and surgical weight loss restored stretch-responsive neuronal activity, highlighting gut mechanosensation as a distinct and potentially reversible metabolic pathway.

• Ceftazidime Workflows for Resistance Research

  2026-09-29

  Ceftazidime connects standardized susceptibility testing with plasmid-localization and transmission studies in clinically relevant Gram-negative models. This practical guide shows how to build reproducible assays for Pseudomonas aeruginosa and carbapenem-resistant Enterobacter cloacae while avoiding common formulation and interpretation errors.

8099 records 1/540 page Next 12345 下5页 Last page